- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
CC-93269 is an investigational, humanized IgG1-based 2+1 T-cell engager (TCE) designed to bind to B-cell maturation antigen (BCMA) on malignant and non-malignant plasma cells and CD3ε on T cells, thus coupling both cell types.1,2 This simultaneous binding is proposed to result in T-cell activation and cytokine release, followed by cytolytic synapse formation and secretion of cytolytic enzymes.1,2
BCMA is a promising target for the treatment of multiple myeloma using various investigational modalities, such as a TCE, because it is universally expressed on the surface of malignant and non-malignant plasma cells and is essential for the survival of these cells.1,3,4 Preclinical studies have shown that anti-BCMA TCEs may cross-link T cells with BCMA-expressing cells, including malignant myeloma cells, potentially leading to increased immune antitumor activity via redirected killing of myeloma and healthy plasma cells by autologous T cells.1,2 Preclinical studies are ongoing to optimize, improve, and assess the potential benefits and risks of CC-93269 as a single agent therapy or in combination with other therapies in multiple myeloma.